07:00 , Sep 5, 2011 |  BC Week In Review  |  Clinical News

APC-100: Phase I/IIa started

Adamis began a U.S. Phase I/IIa trial to evaluate oral APC-100. Adamis has exclusive rights to APC-100 from Colby under a 2010 deal (see BioCentury, March 8, 2010). Adamis Pharmaceuticals Corp. (OTCBB:ADMP), Del Mar, Calif....
08:00 , Mar 8, 2010 |  BC Week In Review  |  Company News

Adamis, Colby, La Jolla Pharmaceutical deal

Adamis received exclusive rights to Colby's CPC-300 , a small molecule signal transduction inhibitor in preclinical testing to treat prostate cancer. Colby received 1 million shares of Adamis, which are valued at $410,000 based on...